GURUFOCUS.COM » STOCK LIST » Europe » France » XPAR » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Beta
Switch to:

Oncodesign Precision Medicine (XPAR:ALOPM) Beta

: N/A (As of Today)
View and export this data going back to 2022. Start your Free Trial

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2023-03-20), Oncodesign Precision Medicine's Beta is Not available.

Oncodesign Precision Medicine Beta Historical Data

The historical data trend for Oncodesign Precision Medicine's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
- -

Oncodesign Precision Medicine Quarterly Data
Dec20 Mar21 Dec21 Jun22
Beta - - - -

Competitive Comparison

For the Biotechnology subindustry, Oncodesign Precision Medicine's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine Beta Distribution

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Beta distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Beta falls in comparison to its industry or sector. The grey bar indicates the Beta's extreme value range as defined by GuruFocus.

Oncodesign Precision Medicine Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Oncodesign Precision Medicine  (XPAR:ALOPM) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Oncodesign Precision Medicine Beta Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Beta provided by Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Oncodesign Precision Medicine logo
Comparable Companies
Traded in Other Exchanges
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines